StreetAccount Summary - Trading higher/lower: EU mid-morning
Biophytis reports FY net income (€24.2M) vs FactSet (€19.3M) [1 est] (€0.13, 0.00)
Biophytis delays publishing annual accounts, will publish by 7-Jul at the latest (€0.13, 0.00)
Biophytis confirms the launch of the Phase 2 OBA clinical trial in obesity (€0.19, 0.00)
Powered by FactSet Research Systems Inc.